These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 20800691)

  • 1. Limbus damage in ocular graft-versus-host disease.
    Pérez RL; Pérez-Simón JA; Caballero-Velazquez T; Flores T; Carrancio S; Herrero C; Blanco B; Gutierrez-Cosio S; Cañete-Campos C; Cruz González F; San-Miguel JF; Hernández-Galilea E; Sánchez-Abarca I
    Biol Blood Marrow Transplant; 2011 Feb; 17(2):270-3. PubMed ID: 20800691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of oral tolerance in bone marrow transplantation recipients suppresses graft-versus-host disease in a semiallogeneic mouse model.
    Nagler A; Ohana M; Alper R; Doviner V; Sherman Y; Rabbani E; Engelhardt D; Ilan Y
    Bone Marrow Transplant; 2003 Aug; 32(4):363-9. PubMed ID: 12900772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post transplant persistence of host cells augments the intensity of acute graft-versus-host disease and level of donor chimerism, an explanation for graft-versus-host disease and rapid displacement of host cells seen following non-myeloablative stem cell transplantation?
    Hirshfeld E; Weiss L; Kasir J; Zeira M; Slavin S; Shapira MY
    Bone Marrow Transplant; 2006 Sep; 38(5):359-64. PubMed ID: 16862165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocular graft-versus-host disease: a review.
    Shikari H; Antin JH; Dana R
    Surv Ophthalmol; 2013; 58(3):233-51. PubMed ID: 23541042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A murine model of graft-vs-host disease after in utero hematopoietic cell transplantation.
    Misra MV; Gutweiler JR; Suh MY; Twark CM; Valim C; Perez-Atayde A; Kim HB
    J Pediatr Surg; 2009 Jun; 44(6):1102-7; discussion 1107. PubMed ID: 19524724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of Ly49A transfected mouse spleen cells on graft versus host disease and graft versus leukemia after haploidentical allogeneic bone marrow transplantation in mice].
    Li Y; Guo K; Chen Y; Song Z; Li J; Deng L
    Zhonghua Xue Ye Xue Za Zhi; 2002 Aug; 23(8):411-4. PubMed ID: 12411044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histological evaluation of acute mucocutaneous graft-versus-host disease in nonmyeloablative hematologic stem cell transplants with an observation predicting an increased risk of progression to chronic graft-versus-host disease.
    Bridge AT; Nelson RP; Schwartz JE; Mirowski GW; Billings SD
    Am J Dermatopathol; 2007 Feb; 29(1):1-6. PubMed ID: 17284954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1-PD-L1 pathway is involved in suppressing alloreactivity of heart infiltrating t cells during murine gvhd across minor histocompatibility antigen barriers.
    Schilbach K; Schick J; Wehrmann M; Wollny G; Simon P; Schlegel PG; Eyrich M
    Transplantation; 2007 Jul; 84(2):214-22. PubMed ID: 17667813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lacrimal gland involvement in graft-versus-host disease: a murine model.
    Hassan AS; Clouthier SG; Ferrara JL; Stepan A; Mian SI; Ahmad AZ; Elner VM
    Invest Ophthalmol Vis Sci; 2005 Aug; 46(8):2692-7. PubMed ID: 16043840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An absence of CCR5 on donor cells results in acceleration of acute graft-vs-host disease.
    Welniak LA; Wang Z; Sun K; Kuziel W; Anver MR; Blazar BR; Murphy WJ
    Exp Hematol; 2004 Mar; 32(3):318-24. PubMed ID: 15003318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MyD88/TLR9 mediated immunopathology and gut microbiota dynamics in a novel murine model of intestinal graft-versus-host disease.
    Heimesaat MM; Nogai A; Bereswill S; Plickert R; Fischer A; Loddenkemper C; Steinhoff U; Tchaptchet S; Thiel E; Freudenberg MA; Göbel UB; Uharek L
    Gut; 2010 Aug; 59(8):1079-87. PubMed ID: 20639251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease.
    Turner BE; Kambouris ME; Sinfield L; Lange J; Burns AM; Lourie R; Atkinson K; Hart DN; Munster DJ; Rice AM
    Transplantation; 2008 Oct; 86(7):968-76. PubMed ID: 18852664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential expression of adhesion and costimulatory molecules in graft-versus-host disease target organs after murine bone marrow transplantation across minor histocompatibility antigen barriers.
    Eyrich M; Burger G; Marquardt K; Budach W; Schilbach K; Niethammer D; Schlegel PG
    Biol Blood Marrow Transplant; 2005 May; 11(5):371-82. PubMed ID: 15846291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulatory effects of mesenchymal stem cells involved in favoring type 2 T cell subsets.
    Lu X; Liu T; Gu L; Huang C; Zhu H; Meng W; Xi Y; Li S; Liu Y
    Transpl Immunol; 2009 Dec; 22(1-2):55-61. PubMed ID: 19695330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody and pre- plus post-transplant prednisone treatments support T cell-depleted stem cell engraftment without drug-induced morbidity.
    D'Costa S; Hurwitz JL
    Bone Marrow Transplant; 2002 Apr; 29(7):553-6. PubMed ID: 11979302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A subset of asialo GM1+ cells play a protective role in the occurrence of graft-versus-host disease in mice.
    De Ruysscher D; Sobis H; Vandeputte M; Waer M
    J Immunol; 1991 Jun; 146(12):4065-70. PubMed ID: 1828259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of lethal graft-versus-host disease by anti-CD137 monoclonal antibody in mice prone to chronic graft-versus-host disease.
    Kim W; Kim J; Jung D; Kim H; Choi HJ; Cho HR; Kwon B
    Biol Blood Marrow Transplant; 2009 Mar; 15(3):306-14. PubMed ID: 19203721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.